Stop TB Partnership and Johnson & Johnson announce price reduction for bedaquiline

Stop TB Partnership Johnson & Johnson
July 6, 2020, 12:06 a.m.
post image

Stop TB Partnership and Johnson & Johnson, with support from USAID and the Global Fund, announce price reduction for bedaquiline for treatment of drug-resistant TB in low- and middle-income countries.

6 July 2020, Geneva, Switzerland – The Stop TB Partnership and Johnson & Johnson – with support from the Global Fund to Fight AIDS, Tuberculosis and Malaria (Global Fund), and the U.S. Agency for International Development (USAID) – today announced joint efforts to help enable low- and middle-income countries to rapidly scale up use of SIRTURO® (bedaquiline) 100 mg tablets in support of new, recently-released World Health Organization (WHO) treatment guidelines.


To read the full press release, click here.


Source: Stop TB Partnership